CAJ | 학술논문

目的：探讨肿瘤标志物CA125联合影像学在肺腺癌患者化疗疗效评价中的价值。方法选取2010年9月—2013年10月就诊于该院的116例肺腺癌患者病例资料,均经病理学确诊、临床分期为III、IV期且未行手术治疗,统计所有患者化疗前及化疗2周期后血清中CA125的水平。结果化学治疗后,116例患者分为3组：疾病部分缓解的患者组(PR)、疾病稳定的患者组(SD)、疾病进展的患者组(PD)。化疗前3组血清CA125水平差异无统计学意义(=0.211,=0.810)；化疗2周期后,3组间血清中CA125的水平差异有统计学意义(=123.09,=0.00)。结论在肺腺癌患者血清中肿瘤标志物CA125可作为早期疗效评价的参考指标之一,值得在临床上应用推广。
목적：탐토종류표지물CA125연합영상학재폐선암환자화료료효평개중적개치。방법선취2010년9월—2013년10월취진우해원적116례폐선암환자병례자료,균경병이학학진、림상분기위III、IV기차미행수술치료,통계소유환자화료전급화료2주기후혈청중CA125적수평。결과화학치료후,116례환자분위3조：질병부분완해적환자조(PR)、질병은정적환자조(SD)、질병진전적환자조(PD)。화료전3조혈청CA125수평차이무통계학의의(=0.211,=0.810)；화료2주기후,3조간혈청중CA125적수평차이유통계학의의(=123.09,=0.00)。결론재폐선암환자혈청중종류표지물CA125가작위조기료효평개적삼고지표지일,치득재림상상응용추엄。
Objective To analyze values of the measurement of serum tumor marker CA125 in the evaluation of chemotherapy efficiency of lung adenocarcinoma.Methods 116 patients with lung adenocarcinoma admitted to our hospital from the February 2010 to October 2013 were selected as the study group and analyzed retrospectively,all patients were confirmed by pathology and the clinical stage were III and IV without surgery.Statistics of CA125 in serum for all patients before chemotherapy and after 2 cycles chemotherapy were measured and compared.Results After chemical therapies,116 patients were divided into three groups: partial response group(PR group),stable disease group(SD group) and progression disease group(PD group).There was no statistically significant between the concentrations of tumor marker CA125 in serum of the three groups before chemical therapy( F=0.211,P=0.810);after 2 cycles of chemotherapy,there was statistically significant between the concentrations of tumor marker CA125 in serum of the three groups statistically significant(F=123.09,P=0.00).Conclusion In the serum of lung cancer patients.